In-Office Vascular Testing: 7 Essential Facts for Independent Practices in 2026

An in-office vascular test is a non-invasive evaluation of the major arteries for signs of peripheral arterial disease (PAD), carotid stenosis, abdominal aortic aneurysm (AAA), and related cardiovascular risk, in at-risk patients. For independent physicians, an in-office testing panel built around the ankle-brachial index (ABI) and complementary autonomic and sudomotor measurements is one of the most efficient ways to identify high-risk patients in a single 7- to 10-minute visit, document medical necessity, and deliver actionable clinical information without referring the patient out.

This guide walks through seven facts that matter most for independent practices considering or already performing in-office vascular testing in 2026: what the test includes, why undiagnosed PAD is so common, how accurate ABI really is, who may warrant testing, and how in-office testing from HealthWright Technologies fits in. For related billing detail, see our ABI CPT code guide and the TM-Flow reimbursement overview.

What Is an In-Office Vascular Testing Panel?

An in-office vascular testing panel is a set of non-invasive measurements that evaluate blood flow and arterial structure in the legs, neck, and abdomen. The standard components in a comprehensive panel are: an ankle-brachial index (ABI) to assess lower-extremity arteries for PAD, a carotid duplex ultrasound to check for plaque or narrowing in the carotid arteries, and an abdominal aortic ultrasound to check for AAA. Many in-office programs add toe-brachial index (TBI) for patients with calcified vessels, pulse volume recording (PVR), autonomic nervous system testing, and sudomotor testing to assess small-fiber nerve function. For patients with calcified vessels, that panel often adds a toe-brachial index for a more accurate reading.

The combined evaluation usually takes under 30 minutes for a basic carotid/ABI/AAA panel, or 7 to 10 minutes for an integrated office-based system like the TM-Flow that bundles ABI, autonomic, and sudomotor testing into a single workflow. None of the components require contrast, radiation, or sedation. Whether testing is appropriate is a clinical-indication question: guidelines support objective testing for symptomatic patients and, at physician discretion, for patients with documented risk factors (see the guideline section below).

Why Does In-Office Vascular Testing Matter So Much in 2026?

Peripheral arterial disease is one of the most undiagnosed conditions in primary care. According to the CDC, PAD affects approximately 6.5 million Americans aged 40 and older. Prevalence in that age group is approximately 4.3%, and that number climbs to 14.5% among adults aged 70 and older. Severe PAD with chronic limb-threatening ischemia, which can lead to amputation, affects about 1.3% of all US adults. Many patients with PAD are never worked up objectively even after leg symptoms or exam findings appear.

Closing that gap for symptomatic and at-risk patients is the reason a structured in-office vascular testing panel is worth building. PAD is both a leg-circulation problem and a powerful marker of systemic atherosclerosis. Patients with PAD have substantially higher risk of myocardial infarction, stroke, and cardiovascular death than the general population. Identifying PAD lets the physician escalate cardiovascular risk reduction (statins, antiplatelet therapy, blood pressure management, smoking cessation support, supervised exercise), document medical necessity for downstream imaging, and follow the patient with objective serial data instead of subjective symptom reports.

What Conditions Does a Vascular Testing Panel Assess?

A comprehensive vascular testing panel is designed to evaluate four overlapping disease processes in symptomatic or at-risk patients:

• Peripheral arterial disease (PAD): narrowing of lower-extremity arteries, identified by an ABI below 0.90 or, when arteries are calcified, by an abnormal TBI.
• Carotid artery stenosis: plaque buildup in the carotid arteries, a major stroke risk factor, identified by carotid duplex ultrasound.
• Abdominal aortic aneurysm (AAA): focal dilation of the abdominal aorta, identified by abdominal ultrasound and graded by maximum diameter.
• Autonomic and sudomotor dysfunction: early signs of small-fiber neuropathy and dysautonomia, often present in diabetes, prediabetes, and cardiometabolic disease. These are picked up by HRV/Valsalva-based autonomic testing and quantitative sudomotor assessment, not by ABI or ultrasound alone. See our autonomic nervous system testing methods and sudomotor testing guide for the underlying physiology.

Bundling these components in one visit converts a vague “let’s keep an eye on it” plan into a documented, billable, and clinically meaningful workup. It also gives the physician an objective baseline to follow over time.

How Accurate Is the Ankle-Brachial Index Within a Vascular Testing Panel?

The ABI is the backbone of any modern vascular testing panel for PAD because it is fast, non-invasive, inexpensive, and well-validated against angiographic standards. A structured review reported that an ABI of 0.90 or lower achieves specificity in the range of 83% to 99% and accuracy of approximately 72% to 89% for detecting stenosis greater than 50%. A Cochrane review reported, from a single 85-patient study, that in femoropopliteal disease oscillometric ABI showed sensitivity of 97% and specificity of 89%, while doppler ABI performed by untrained personnel showed sensitivity of 95% and specificity of 56% (Crawford et al., Cochrane Database of Systematic Reviews, 2016). Reported intraobserver variability ranges from 7.3% to 12% (Al-Qaisi et al., Vascular Health and Risk Management, 2009).

The well-known limitation is that ABI sensitivity falls in patients with media calcification, most commonly long-standing diabetes and advanced chronic kidney disease, where the ankle arteries become non-compressible and ABI can be falsely normal or falsely elevated. That is why a complete vascular testing panel pairs ABI with TBI (which uses the digital arteries, typically spared from calcification) and, ideally, pulse volume recording for waveform confirmation. The American Heart Association’s measurement and interpretation guidance for ABI supports this combined approach in higher-risk populations.

Who May Warrant In-Office Vascular Testing?

Guideline-based screening for asymptomatic adults is nuanced. The US Preventive Services Task Force (USPSTF) currently gives a grade I (insufficient evidence) for ABI screening in asymptomatic adults without known PAD, CVD, or severe CKD. That grade does not mean ABI is unhelpful. It means the USPSTF has not found enough evidence to make a population-level for-or-against statement about routine screening in healthy asymptomatic adults.

For at-risk and symptomatic patients, the clinical picture is very different. Vascular societies and the AHA support objective ABI evaluation in patients with claudication symptoms, non-healing wounds, age over 65, diabetes with neuropathy, history of smoking, or other established cardiovascular disease. In practice, an in-office vascular testing panel is most useful for:

Specialty settings change which of those risk factors show up most often. Pain management practices, for example, see patients whose leg and foot symptoms are already documented but are easily attributed to neuropathy or to the spine, a differential covered in our guide to vascular testing for pain management practices. Rheumatology clinics face a related problem from a different direction, because inflammatory disease is itself a recognized cardiovascular risk enhancer and lower-limb hardware rules part of the study out, as covered in our guide to vascular testing for rheumatology practices. Geriatric and long-term care panels add a third variation, because older patients frequently under-report the symptom that would prompt the study at all, as covered in our guide to vascular testing for geriatric practices.

• Adults age 65+ with any cardiovascular risk factor
• Adults age 50+ with diabetes, hypertension, hyperlipidemia, or smoking history
• Patients reporting leg pain with walking that resolves with rest (classic claudication)
• Patients with non-healing foot wounds, ischemic rest pain, or known neuropathy
• Patients with established cardiovascular or cerebrovascular disease being evaluated for systemic atherosclerotic burden
• Medicare beneficiaries eligible for the SAAAVE Act AAA ultrasound, a one-time covered screening for men 65-75 who have smoked at least 100 cigarettes in their lifetime, and for individuals with a family history of AAA, when referred by a physician or a qualified nonphysician practitioner

For each of these groups, documenting risk factors and the clinical indication is the critical step that supports both medical decision-making and clean reimbursement.

How Do Independent Practices Add In-Office Vascular Testing?

Most independent practices add vascular testing through one of three paths: refer to a vascular lab, partner with a mobile testing service, or perform the test in-house with a dedicated device. In-house has become substantially more practical with integrated platforms designed for primary care, cardiology, internal medicine, endocrinology, and pain management.

Settle the regulatory question early, because it is simpler than most practices expect. A physiologic study collects no specimen, so CMS places it outside the CLIA program entirely. Our guide on whether in-office vascular testing needs a CLIA certificate quotes what CMS actually says and covers the point where practices still get caught.

For the broader clinical and quality-measure case behind bringing this in-house, see why non-invasive cardiovascular diagnostics are becoming standard in primary care.

The TM-Flow System, distributed in the United States by HealthWright Technologies, was built around exactly this use case. A single 7 to 10 minute test session delivers ABI/TBI and pulse volume recording (CPT 93923), cardiovagal autonomic testing (CPT 95921), and sudomotor function testing (CPT 95923). The device is FDA-cleared. Implementation typically includes device training, clinical protocols, payer credentialing support, and ongoing billing guidance. Those elements determine whether an in-house vascular testing program actually generates the clinical and financial value it should. See our CMAT Advantage vs standard ABI testing comparison for a side-by-side view, and the PAD testing for independent practices article for the broader workflow.

Carotid duplex and AAA ultrasound remain separate modalities; many practices that perform in-house ABI/autonomic testing still refer carotid and AAA studies to a vascular lab. The combination of in-office ABI/autonomic/sudomotor testing plus referred carotid and AAA imaging gives a complete vascular testing panel without requiring a full vascular ultrasound suite on site.

What Documentation Supports a Clean Vascular Testing Claim?

Reimbursement for a vascular testing panel depends on documentation that ties the test to a clinical indication, not on the test itself. For each CPT code in the panel, the chart should include: documented risk factors or symptoms supporting medical necessity, the specific question the test was ordered to answer, the test performance details (date, equipment, protocol), a signed physician interpretation and report (not just the device printout), and ICD-10 codes consistent with the indication. Frequency limits vary by payer and are set in the applicable LCD; repeat testing is generally covered only when a new or changed documented indication supports it, so confirm the limit with your MAC.

Medicare reimbursement is set by the annual Physician Fee Schedule and varies by locality; verify current rates with the CMS PFS Look-up Tool. Rates for CPT 95921 and 95923 vary by Medicare locality. Practices should verify exact rates using the CMS PFS Look-up Tool and consult the AHA’s PAD patient resources for population context.

Frequently Asked Questions About In-Office Vascular Testing

How long does an in-office vascular test take?

A basic in-office vascular test using an integrated platform like TM-Flow takes 7 to 10 minutes for ABI, autonomic, and sudomotor measurements. A full panel that also includes carotid duplex and AAA ultrasound at a vascular lab typically takes under 30 minutes of patient time across the two studies. None of the components require contrast, radiation, or sedation.

Does Medicare cover in-office vascular testing?

Medicare covers the diagnostic components of in-office vascular testing when medical necessity is documented. ABI/TBI (CPT 93923) and autonomic and sudomotor testing (CPT 95921, 95923) are reimbursable under standard Medicare rules when the chart supports an appropriate indication. Medicare also covers a one-time AAA ultrasound under the SAAAVE Act for at-risk beneficiaries on referral from a physician or a qualified nonphysician practitioner. Coverage of asymptomatic ABI screening varies. Practices should verify medical necessity and indication-specific coverage with the relevant Medicare Administrative Contractor.

Is an in-office vascular test the same as an EKG?

No. An in-office vascular test evaluates the arteries, meaning blood flow, vessel structure, and (in the case of autonomic add-ons) nerve control of cardiovascular function. An EKG records the electrical activity of the heart muscle. The two studies answer different clinical questions and are commonly ordered together when both cardiac and vascular workup is indicated. The TM-Flow System measures autonomic nervous system function, not EKG tracings.

How accurate is the ankle-brachial index in patients with diabetes?

ABI maintains high specificity in patients with diabetes but its sensitivity is limited in the presence of medial arterial calcification, which is more common in long-standing diabetes and advanced chronic kidney disease. In those patients, an ABI value can be falsely normal or falsely elevated. Pairing ABI with toe-brachial index (TBI) and pulse volume recording substantially improves diagnostic accuracy in this population because the digital arteries are typically spared from calcification.

Can an in-office vascular test be performed when it is medically indicated for a symptomatic or at-risk patient?

Yes, when the medical indication is documented. Many practices integrate ABI/autonomic/sudomotor testing into the visit for at-risk or symptomatic patients with diabetes, hypertension, hyperlipidemia, or smoking history. Each CPT code in the vascular testing panel is billed separately from the wellness visit code (G0438 or G0439), with appropriate modifiers when required by payer policy.

Ready to Add In-Office Vascular Testing?

An in-office vascular testing panel built around the TM-Flow System gives independent practices a 7 to 10 minute, FDA-cleared, payer-recognized workflow for identifying PAD and small-fiber neuropathy risk objectively, once symptoms or exam findings are documented. The clinical case is straightforward: when a patient presents with leg symptoms or exam findings that suggest PAD, objective diagnosis lets the physician change the cardiovascular risk trajectory.

To discuss the CMAT Advantage bundle, device pricing, training, payer credentialing, and implementation for your practice, contact HealthWright Technologies at contact@healthwrighttechnologies.com or call (678) 322-7146. Our office is at 60 Bear Creek Marina Road, Mansfield, GA 30055. Learn more on the products page, the partnership page, or the contact page.

Medical/billing disclaimer: This article is intended for licensed healthcare professionals and is for general informational purposes only. It does not constitute medical, billing, or legal advice. Clinical decisions about screening, diagnosis, and treatment should be based on individualized patient evaluation and current evidence. Reimbursement amounts and coverage vary by payer, region, and clinical indication; providers are responsible for verifying coverage and coding accuracy with each payer. CPT® is a registered trademark of the American Medical Association.